GLP-1s and Oral Progesterone: When to Review Your HRT

The question is protection, not whether HRT stops weight loss

If you use oral progesterone or another oral progestogen with menopausal estrogen, ask your hormone prescriber to review the regimen when starting or increasing a GLP-1. Do not change the dose yourself. British guidance raises a possible absorption concern, while explicitly acknowledging that direct studies of HRT effectiveness and endometrial outcomes are missing¹.

That uncertainty deserves a useful conversation, rather than either a reassuring dismissal or an alarming claim that your hormones have stopped working. Bring the names and routes of both hormone medicines. An estrogen patch paired with a progesterone capsule is still a partly oral regimen. A patch on your skin does not tell the clinician how the uterine lining is being protected.

This is a different question from whether hormones make weight loss harder. Our HRT and weight-loss evidence review addresses that concern. Here the decision is whether the hormone plan remains appropriate while another prescription is changing.

Why the uterus changes the conversation

For a woman with a uterus taking systemic estrogen, a progestogen is generally needed to reduce the risk of the uterine lining becoming overgrown. ACOG explains why estrogen alone and estrogen-plus-progestin therapy have different uses². Progesterone is one type of progestogen; the broader term also includes synthetic medicines. They are not all interchangeable products.

The purpose is not simply to produce a particular bleeding pattern or improve sleep. Someone can feel better on estrogen and still need the appropriate protection alongside it. Conversely, a change in symptoms cannot establish that progesterone absorption has fallen. The relevant assessment considers the estrogen exposure, progestogen, route, schedule, medical history and bleeding together.

If you have had a hysterectomy, tell the clinician what surgery was performed and why. Do not assume a generic article about an intact uterus applies to your regimen. Your own prescription may have a different rationale that needs explaining before anything is changed.

What the British guidance actually says

The British Menopause Society's April 2025 clinician tool discusses potential reduced absorption of oral HRT components because incretin medicines delay stomach emptying. It distinguishes oral preparations from routes that do not depend on gut absorption, and suggests clinician consideration of different progestogen arrangements. Its recommendations are pragmatic expert opinion, not proof that a particular capsule has failed¹.

The document is UK professional guidance. Its discussion includes products and routes whose licensing or indications may differ in the United States. A recommendation encountered in a British forum is therefore a reason to ask your U.S. clinician about the underlying concern, not an instruction to reproduce the same prescription.

This distinction also matters when someone shares a progesterone dose online. A dose chosen for another woman's estrogen regimen, uterine history or bleeding cannot establish yours. More medicine is not automatically better protection, and an online conversion between routes is not a substitute for prescribing advice.

Professors Annice Mukherjee, Sadaf Ghaem-Maghami and Akheel Syed developed that tool with the BMS medical advisory council⁵. Their advice, published in the British Menopause Society’s clinician series, includes a telling instruction: “Uncertainty should be shared with the patient”¹. That matters if you feel caught between a clinician who sounds certain and conflicting advice online. Ask what is known, what is inferred, and how your preferences fit the plan; uncertainty should be explained to you, not left for you to discover afterward.

The U.S. contraception warning answers another question

The U.S. Zepbound label gives a specific instruction for users of oral hormonal contraception: use a nonoral method or add barrier protection for four weeks after starting and after each increase³. That instruction concerns pregnancy prevention. It is not a studied HRT progesterone dosing formula.

A contraceptive pill, a progesterone capsule prescribed with menopausal estrogen and a vaginal estrogen treatment can serve different purposes. They may appear together in the same medicine list without having the same interaction evidence. Ask the prescriber to identify which drug provides contraception and which provides endometrial protection.

For the everyday contraceptive warning, see our GLP-1 and birth-control guide. Do not assume a menopausal hormone prescription is also your contraception. If pregnancy is still possible, that needs its own plan, even when periods have become infrequent.

Bring a short, accurate medication record

The most useful record can fit on one page. Include the estrogen product and route, the progestogen product and route, whether it is taken continuously or on selected days, and the GLP-1 product, dose and dates of recent changes. Add missed hormone doses, vomiting and any new bleeding. Photographing the boxes may help avoid confusing similar brand names.

Ask one practical question at the end: who is responsible for coordinating the two prescriptions? A telehealth weight-management service and a separate menopause clinician may each hold only half the list. Make sure the final plan reaches both offices rather than expecting you to reconcile contradictory instructions.

Bleeding is a reason to assess, not to diagnose an interaction

Some bleeding can occur when hormone therapy starts or changes, but a new pattern should be discussed with the treating clinician. ACOG describes assessment of abnormal uterine bleeding and emphasizes the importance of the patient's age, medical history and symptoms⁴. Bleeding after menopause should not simply be labeled a medication side effect at home.

Report what happened: spotting or heavier flow, whether it recurs, pain, dizziness, missed medicines and the timing relative to hormone or GLP-1 changes. Severe bleeding with faintness, chest symptoms or shortness of breath needs urgent assessment. Do not spend days trying a different hormone dose before seeking help for concerning symptoms.

Our guide to vaginal symptoms and unexpected bleeding separates several problems that can be mistaken for one another. Dryness, infection and uterine bleeding are not the same diagnosis. Neither symptom improvement nor a reassuring story from another patient rules out a cause that needs examination.

Agree on a follow-up plan you can actually use

A useful review does not have to end in a prescription change. It may end in confirmation of the current regimen, a different route, investigation of bleeding, or a plan to reassess after the next GLP-1 increase. The important part is knowing what was decided and what would prompt earlier contact.

Ask when to report new bleeding, what to do if vomiting prevents taking an oral medicine, and whether another clinician needs the updated list. If a route is changed, ask how the transition is managed rather than stopping one medicine before the replacement is arranged. Keep instructions with your medication record.

The broader perimenopause and appetite discussion explains why these prescriptions often meet at the same life stage. Combining care should make the responsibilities clearer. The evidence supports a review of your circumstances; it does not support a universal claim that GLP-1s make HRT ineffective or a universal extra progesterone dose.